Burton L. Eisenberg, M.D.
Title(s):
Professor of Surgery
Department(s):
Surgery
Education:
1974 University of Tennessee School of Medicine - MD
1970 University of Connecticut - BA
Programs:
Norris Cotton Cancer Center
Websites:
http:
Contact Information:
Norris Cotton Cancer Center
1 Medical Center Drive
Lebanon NH 03756
Office: Academic: 603-653-3613
Phone: Clinic: 603-650-9479
Fax: 603-653-9003
Assistant: Lydia Walker
Asst. Phone: 603-653-3613
Asst. Email: Lydia.L.Walker@Dartmouth.edu
Professional Interests:
Clinic Trials in Soft Tissue Sarcoma, as Chair of the RTOG Sarcoma Committee
Comprehensive Breast Oncology Program
Gastrointestinal Clinical Oncology Group
Molecular Therapeutics Research Program
Grant Information:
National Cancer Institute (NCI) Grant 3U10 CA21661-27; Gleevec Induced Differential Gene Expression Patterns in Gastrointestinal Stromal Tumors (GIST) with Correlation to Clinical Response; Principal Investigator: Burton L. Eisenberg, M.D.; 9/1/02-8/31/05
Tobacco Formula Grant 9151-01; Identification of Genetic Markers Responsive to Gleevec in Gastrointestinal Stromal Tumors; Co-Principal Investigator: Burton L. Eisenberg, M.D.; 1/1/003-12/31-03
National Institutes of Health (NIH) RO1 CA106588-01; The Molecular Actions of Imatinib Mesylate in Gastrointestinal Stromal Tumors (GIST's); PI: A.K. Godwin, Ph.D., Co-PI: B.L. Eisenberg, M.D.; 4/1/04-3/31/09
Selected Publications: |
|
Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CDM, Sandau K, McDougall K, Ou W, Chen CJ, Fletcher JA Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors. J Clin Onc 24(29):4764-4774, October 10, 2006 Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 24(4):619-625, 2006 Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M, Godwin AK Therapeutic Effect of Imatinib in Gastrointestinal Stromal Tumors: AKT Signaling Dependent and Independent Mechanisms. Cancer Res, May 15;66(10):5477-5486, 2006 Movsas B, Diratzouian H, Hanlon A, Cooper H, Eisenberg B, et al Phase II Trial of Preoperative Chemoradiation with a Hyperfractionated Radiation Boost in Locally Advanced Rectal Cancer. Am J Clin Onc 29(5):435-441, October 2006 Eisenberg B Combining Imatinib with Surgery in GIST: Rationale and Ongoing Trials. Clin Colorectal Cancer, 6 Suppl 1:S24-29, November 2006 Demetri GD, von Mehren M, Joensuu H, Heinrich MC, Fletcher JA, Corless CL, Fletcher CDM, Eisenberg B, et al Long-term Clinical Outcomes of Imatinib Treatment in Patients with Advanced Gastrointestinal Stromal Tumors. J Clin Onc (in press) Eisenberg BL Combined-Modality Strategy for Gastrointestinal Stromal Tumors. Semin Oncol 33(6 Suppl 11):S75-78, December 2006 Eisenberg BL, Hughes DT The Synthetic Triterpenoid CDDO-Im Inhibits Fatty Acid Synthase Expression and has Antipoliferative and Proapoptotic Effects in Human Liposarcoma Cells. Cancer Investigation (in press) Tarn C, Rink L, Merkel E, Flieder D, Koumbi D, Testa J, Eisenberg B, von Mehren M, Godwin, AK Insulin-like Growth Factor 1 Receptor: A Potential Therapeutic Target for Gastrointestinal Stromal Tumors. Cancer Research (in press) 2007 Ozols RF, Herbst RS, Colson YL, Gralow J, Bonners J, Curran WJ, Eisenberg BL, Banz PA, Kramer BS, et al Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening - A Report from the American Society of Clinical Oncology. J Clin Oncol 25:146-162, January 2007 |
|